Selected for the Ministry of SMEs and Startups’ Technology Development Project
"Aiming for Clinical Entry"

Huons is joining forces with three biotech startups to jointly develop new drug candidates based on different modalities, including messenger RNA (mRNA), antibody-drug conjugates (ADC), and peptides. The company plans to accelerate progress toward the clinical stage based on these partnerships.

Huons Teams Up with Three Biotech Startups for Joint New Drug Development... "Expanding External Research Model" View original image

On September 14, Huons announced that three separate consortia formed with Surginex, Pinobio, and Pulsein Myers have been selected for the "2026 Pharmaceutical & Biotech Venture Collaboration-Based Technology Development Project" pipeline joint development track hosted by the Ministry of SMEs and Startups. This year, a total of 10 projects were selected for this track, with Huons participating as a co-research and development institution in three of them.


The Collaboration-Based Technology Development Project for pharmaceutical and biotech ventures is a government-supported initiative that encourages major/midsize pharmaceutical companies and biotech startups to jointly advance promising drug candidates. The program is overseen by the Ministry of SMEs and Startups, with execution managed by the Korea Technology and Information Promotion Agency for SMEs (TIPA). Huons will leverage its own chemical-manufacturing-control (CMC), production, non-clinical and clinical development, and regulatory affairs (RA) expertise, combining these with biotech startups’ proprietary technologies to drive each candidate toward clinical entry.


Huons plans to expand this joint development beyond simply fulfilling a government project, aiming to adopt an open innovation-based "external research and development (External R&D)" model that connects promising early-stage technologies from biotech startups to non-clinical and clinical phases.



Soo Young Song, CEO of Huons, said, “The selection of these three joint new drug development government projects is a tangible outcome of Huons’ ongoing commitment to open innovation. By collaborating with biotech ventures possessing innovative technologies in diverse modalities, we will step up our efforts toward the shared goal of clinical entry.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing